The Vioxx recall is just the latest of several episodes this year that have prompted criticism of the FDA and Senate hearings. A panel talks about the drug approval process, post-marketing safety surveillance, and how the agency’s work affects Americans’ health and safety.

Guests

  • Marc Kaufman Reporter on the national desk of "The Washington Post"
  • Dr. Jerry Avorn Author of "Powerful Medicines," professor of medicine at Harvard Medical School, and chief of the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital in Boston
  • Alan Goldhammer, PhD Associate vice president for regulatory affairs at the Pharmaceutical Research and Manufacturers of America (PhRMA)
  • Sen. Charles Grassley (R-Iowa), ranking member of the Senate Finance Committee
  • Dr. Sandra Kweder Deputy director of the FDA's Office of New Drugs

Related Links

Topics + Tags

Comments

comments powered by Disqus
Most Recent Shows

The Tuskegee Study, 50 Years Later

Friday, Jul 29 2022Fifty years after the Tuskegee study, Diane talks to Harvard's Evelynn Hammonds about the intersection of race and medicine in the United States, and the lessons from history that can help us understand health inequities today.